Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of the pathogens that are the cause of pneumonia by the battlefield hypothesis.
Hirama T, Yamaguchi T, Miyazawa H, Tanaka T, Hashikita G, Kishi E, Tachi Y, Takahashi S, Kodama K, Egashira H, Yokote A, Kobayashi K, Nagata M, Ishii T, Nemoto M, Tanaka M, Fukunaga K, Morita S, Kanazawa M, Hagiwara K. Hirama T, et al. Among authors: tanaka m, tanaka t. PLoS One. 2011;6(9):e24474. doi: 10.1371/journal.pone.0024474. Epub 2011 Sep 1. PLoS One. 2011. PMID: 21909436 Free PMC article.
Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C.
Omori-Mizuno Y, Nakayama N, Inao M, Funyu J, Asabe S, Tomita K, Nishikawa K, Hosoda Y, Tanaka M, Hashimoto Y, Yakabi K, Koshima Y, Mochida S. Omori-Mizuno Y, et al. Among authors: tanaka m. J Gastroenterol Hepatol. 2015 Sep;30(9):1384-90. doi: 10.1111/jgh.12949. J Gastroenterol Hepatol. 2015. PMID: 25778685 Clinical Trial.
A multicenter study to clarify the optimal HCV-RNA negative period during combined therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis caused by HCV genotype 2.
Nagoshi S, Koshima Y, Nakamura I, Funyu J, Sekine C, Harada Y, Nishikawa K, Yoshida T, Matsui A, Sotome N, Toshima K, Takegoshi S, Shiomi M, Tanaka M, Saito A, Fujiwara K, Mochida S. Nagoshi S, et al. Among authors: tanaka m. Intern Med. 2012;51(1):9-15. doi: 10.2169/internalmedicine.51.6237. Epub 2012 Jan 1. Intern Med. 2012. PMID: 22214617 Free article. Clinical Trial.
Myeloablative conditioning in cord blood transplantation for acute myeloid leukemia patients is efficacious only until age 55.
Oshima S, Arai Y, Kondo T, Yano S, Hirabayashi S, Uchida N, Onizuka M, Miyakoshi S, Tanaka M, Takahashi S, Hayashi M, Kawakita T, Uehara Y, Ota S, Izumi T, Sawa M, Nishida T, Katayama Y, Nagafuji K, Kato K, Ichinohe T, Atsuta Y, Yanada M. Oshima S, et al. Among authors: tanaka m. Bone Marrow Transplant. 2025 Jan 21. doi: 10.1038/s41409-025-02508-2. Online ahead of print. Bone Marrow Transplant. 2025. PMID: 39838078
15,435 results
You have reached the last available page of results. Please see the User Guide for more information.